arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

NovoCure Ltd

NVCR
$13.56 ▼ -1.04 (-7.16%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
14 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

NovoCure Ltd faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.5B
Dividend Yield —
Revenue Growth 8.3% ↘
Op. Margin -23.5% ↗
ROIC -28.7% ↗
FCF / Share $-0.68 ↘
Trailing P/E —
Price / Book 4.5x
FCF Yield —
Debt / Equity 0.57
info Valuation on last close. End-of-day price, Nov 5, 2026.

14-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$655.35M
↑ +8.3% —
Net Income Profit after all expenses
$-136.23M
↑ +19.2% —
Operating Margin Operating profit as % of sales
-23.5%
↑ +16.7% 9th
FCF / Share Free cash flow per share
$-0.68
↓ -5.8% —
Long-Term Debt Long-term obligations
$195.05M
↑ +100.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
10
Returns ↓
19
Financial Health ↓
40
Cash Quality
42

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 14 years · 52 quarters